C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease

被引:22
|
作者
Fan, Zhiwen [1 ]
Sun, Xinyue [2 ]
Chen, Xuelian [2 ]
Liu, Huimin [2 ]
Miao, Xiulian [3 ]
Guo, Yan [3 ]
Xu, Yong [2 ,3 ]
Li, Jie [4 ,5 ,8 ]
Zou, Xiaoping [6 ,7 ,8 ]
Li, Zilong [2 ,3 ,9 ]
机构
[1] Nanjing Univ, Nanjing Drum Tower Hosp, Sch Med, Dept Pathol, Nanjing, Peoples R China
[2] China Pharmaceut Univ, Dept Pharmacol, State Key Lab Nat Med, Nanjing, Peoples R China
[3] Liaocheng Univ, Inst Biomed Res, Coll Life Sci, Liaocheng, Peoples R China
[4] Nanjing Univ, Nanjing Drum Tower Hosp, Med Sch, Dept Infect Dis, Nanjing, Peoples R China
[5] Nanjing Univ, Inst Viruses & Infect Dis, Nanjing, Peoples R China
[6] Nanjing Univ, Taikang Xianlin Drum Tower Hosp, Med Sch, Dept Gastroenterol, Nanjing, Peoples R China
[7] Nanjing Univ, Nanjing Drum Tower Hosp, Sch Med, Dept Gastroenterol, Nanjing, Peoples R China
[8] Nanjing Drum Tower Hosp, Nanjing 210008, Peoples R China
[9] China Pharmaceut Univ, Nanjing 211198, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-alcoholic fatty liver disease; Hepatocytes; Transcriptional regulation; Chemokine; Inflammation; HEPATIC INFLAMMATION; EOTAXIN; FIBROSIS; BINDING; INJURY; MODEL; MICE; PREVALENCE; DISRUPTION; EXPRESSION;
D O I
10.1016/j.jhepr.2023.100805
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is characterised by accelerated lipid deposition, aberrant inflammation, and excessive extracellular matrix production in the liver. Short of effective intervention, NAFLD can progress to cirrhosis and hepatocellular carcinoma. In the present study we investigated the involvement of the C-C motif ligand 11 Methods: NAFLD was induced by feeding mice with a high-fat high-carbohydrate diet. CCL11 targeting was achieved by genetic deletion or pharmaceutical inhibition. The transcriptome was analysed using RNA-seq. Results: We report that CCL11 expression was activated at the transcription level by free fatty acids (palmitate) in hepatocytes. CCL11 knockdown attenuated whereas CCL11 treatment directly promoted production of pro-inflammatory/pro-lipogenic mediators in hepatocytes. Compared with wild-type littermates, CCL11 knockout mice displayed an ameliorated phenotype of NAFLD when fed a high-fat high-carbohydrate diet as evidenced by decelerated body weight gain, improved insulin sensitivity, dampened lipid accumulation, reduced immune cell infiltration, and weakened liver fibrosis. RNA-seq revealed that interferon regulatory factor 1 as a mediator of CCL11 induced changes in hepatocytes. Importantly, CCL11 neutralisation or antagonism mitigated NAFLD pathogenesis in mice. Finally, a positive correlation between CCL11 expression and NAFLD parameters was identified in human patients. Conclusions: Our data suggest that CCL11 is a novel regulator of NAFLD and can be effectively targeted for NAFLD intervention. Impact and implications: Non-alcoholic fatty liver disease (NAFLD) precedes cirrhosis and hepatocellular carcinoma. In this paper we describe the regulatory role of CCL11, a C-C motif ligand chemokine, in NAFLD pathogenesis. Our data provide novel & COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
引用
收藏
页数:15
相关论文
共 50 条
  • [1] The C-C motif chemokine ligand 11 contributes to alcoholic liver disease
    Li, Jichen
    Wang, Ben
    Wang, Shunjie
    Wang, Jieguo
    Zhou, Anqi
    Gong, Shanwen
    Wang, Yu
    Miao, Xiulian
    Guo, Yan
    Wang, Hao
    Ge, Hailong
    LIFE SCIENCES, 2025, 363
  • [2] Uncovering a novel potential target in non-alcoholic fatty liver disease
    Praestholm, Stine Marie
    Correia, Jorge
    Ruas, Jorge
    JOURNAL OF HEPATOLOGY, 2023, 78 : S741 - S741
  • [3] The immune response as a therapeutic target in non-alcoholic fatty liver disease
    Ortiz-Lopez, Nicolas
    Fuenzalida, Catalina
    Soledad Dufeu, Maria
    Pinto-Leon, Araceli
    Escobar, Alejandro
    Poniachik, Jaime
    Pablo Roblero, Juan
    Valenzuela-Perez, Lucia
    Beltran, Caroll J.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] C-C Motif Chemokine Ligand 5 (CCL5): A Potential Biomarker and Immunotherapy Target for Osteosarcoma
    Zheng, Heng
    Wang, Yichong
    Li, Fengfeng
    CURRENT CANCER DRUG TARGETS, 2024, 24 (03) : 308 - 318
  • [5] The C-C motif chemokine ligands CCL5, CCL11, and CCL24 induce the migration of circulating fibrocytes from patients with severe asthma
    Isgro, M.
    Bianchetti, L.
    Marini, M. A.
    Bellini, A.
    Schmidt, M.
    Mattoli, S.
    MUCOSAL IMMUNOLOGY, 2013, 6 (04) : 718 - 727
  • [6] PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease
    Sachan, Vatsal
    Le Devehat, Mailys
    Roubtsova, Anna
    Essalmani, Rachid
    Laurendeau, Jean-Francois
    Garcon, Damien
    Susan-Resiga, Delia
    Duval, Stephanie
    Mikaeeli, Sahar
    Hamelin, Josee
    Evagelidis, Alexandra
    Chong, Michael
    Pare, Guillaume
    Chernetsova, Elizabeta
    Gao, Zu-Hua
    Robillard, Isabelle
    Ruiz, Matthieu
    Trinh, Vincent Quoc-Huy
    Estall, Jennifer L.
    Faraj, May
    Austin, Richard C.
    Sauvageau, Martin
    Prat, Annik
    Kiss, Robert S.
    Seidah, Nabil G.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 150
  • [7] Potential use of C-phycocyanin in non-alcoholic fatty liver disease
    Ma, Peng
    Huang, Rongrong
    Jiang, Jingyao
    Ding, Yuan
    Li, Tingting
    Ou, Yu
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 526 (04) : 906 - 912
  • [8] Oleuropein as a Therapeutic Agent for Non-alcoholic Fatty Liver Disease During Hepatitis C
    Mohammadjavad Sotoudeheian
    SeyedAhmad Hoseini
    Seyed-Mohamad-Sadegh Mirahmadi
    Navid Farahmandian
    Hamidreza Pazoki-Toroudi
    Revista Brasileira de Farmacognosia, 2023, 33 : 688 - 695
  • [9] Oleuropein as a Therapeutic Agent for Non-alcoholic Fatty Liver Disease During Hepatitis C
    Sotoudeheian, Mohammadjavad
    Hoseini, SeyedAhmad
    Mirahmadi, Seyed-Mohamad-Sadegh
    Farahmandian, Navid
    Pazoki-Toroudi, Hamidreza
    REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY, 2023, 33 (04): : 688 - 695
  • [10] [11C]acetat PET for diagnosis of non-alcoholic fatty liver disease
    Nejabat, Marzieh
    Leisser, Asha
    Karanikas, Georgios
    Mayerhoefer, Marius
    Wadsak, Wolfgang
    Mitterhauser, Markus
    Hacker, Marcus
    Haug, Alexander
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)